Cambrex, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), is investing $24 million in a new highly potent API manufacturing facility in Charles City, Iowa.
Investment
The new facility, based in the Iowa plant, will offer a 4,500 sq ft production area for the operation of an occupational exposure limit (OEL) down to 0.1 µg/m3 and will have a total reactor capacity of 2,200 gallons.
Additionally, the investment will incorporate a reconfiguration of the existing small scale manufacturing area, which will provide a single high containment building to support early stage development and manufacturing.
“This expansion is in line with Cambrex’s commitment to ongoing investment in small molecule manufacturing, as well as responding to the rising number of APIs that require specialized handling due to potency and toxicity,” commented Shawn Cavanagh, COO of Cambrex. “Cambrex has built a strong reputation in the clinical-scale supply of potent, and extremely potent molecules, and the flexibility that this facility will give allows us to effectively handle projects throughout their development and commercial life-cycle.”
Completion of construction and installation of all new equipment is anticipated by the first quarter of 2019.